B this journal,' demonstrate that recombinant human granulocyte colony-stimulating factor (G-CSF) can be administered safely to normal blood donors for purposes of collecting granulocyte concentrates containing extraordinarily high yields of neutrophils (PMNs). Because one of the major factors diminishing the efficacy of granulocyte transfusions (GTX) as treatment for infections in neutropenic patients has been the relatively small dose of PMNs available in granulocyte concentrates, the prospect raised by this report of being able to transfuse substantially larger numbers of PMNs justifies a reassessment of the utility of therapeutic GTX. Is there a role in clinical medicine for an improved granulocyte concentrate?
Bacterial, yeast, and fungal infections are an undeniable consequence of both severe neutropenia (<0.5 X lo9 PMNs/ L blood) and disorders of abnormal PMN function. In many studies, benefit has been shown for GTX as treatment for infections in certain clinical settings in animals and in humans.* However, enthusiasm has waxed and waned. In the 1970s, zealous advocates of GTX stated that it was unnecessary, unwarranted, and perhaps even unethical to conduct controlled, clinical trials to define the seemingly obvious efficacy of therapeutic GTX.3-5 Despite such enthusiasm and the plethora of published reports supporting the transfusion of granulocyte concentrates, the use of GTX has diminished strikingly. Although this can be explained, in part, by the development of more effective antibiotics and alternative therapies such as intravenous (IV) gammaglobulin and recombinant myeloid growth factors, many physicians hold strong negative opinions about the value of GTX, for reasons that are not readily apparent. At present, many physicians believe that there is little, if any, role for GTX in the management of infected neutropenic patients! In my view, this excessively negative attitude is unjustified scientifically, and it is reasonable to critically assess both the role of therapeutic GTX in the light of current standards of practice and the feasibility of using G-CSF, per the method of Bensinger et al,' to stimulate PMN donors.
ROLE OF THERAPEUTIC GTX IN NEUTROPENIC PATIENTS
A detailed analysis of 30 papers reporting use of GTX plus antibiotics to treat infections in severely neutropenic patients (usually <0.5 PMN X 109/L blood) has been presented previously.' In summary, data from all 30 studies are displayed in Table 1 . Patients were tabulated according to the index infection that prompted GTX therapy. Patients were counted only once, and those with septicemia were listed in the s e p ticemia section, whether or not they exhibited another infection such as pneumonia, abscess, etc. All patients administered GTX for a designated type of infection were tabulated in the column labeled "treated." Patients for whom the actual course and mortality of the infection could be clearly documented were then listed again in the "evaluable" column. GTX were considered to be successful, if so stated by the investigator. Many of the 30 reports were of uncontrolled studies consisting of small numbers of patients with a diversity of underlying diseases, types of infections, antimicrobial therapy, and GTX management (ie, variable dose and quality of PMNs). Because of these complex issues, combining data from multiple reports is of limited value. It was done here primarily to document the breadth of experience reported. It is clear that information regarding the efficacy of GTX for specific types of infection is fairly limited, with the possible exception of bacterial septicemia.
To obtain more definitive information, the seven controlled studies were analyzed in more detail.'-14 In the seven controlled studies, the response of infected, neutropenic patients to treatment with GTX plus antibiotics (study group) was compared with that of comparable patients, evaluated concurrently, who were administered antibiotics alone (control group). The results of these seven studies are presented in Table 2 . In three of the seven studies a significant overall benefit for GTX was found."-13 In two additional overall success was not demonstrated for GTX, but certain subgroups of patients were found to benefit significantly. One study with partial success was the first controlled study of GTX reported.' In this early study, many patients received an inadequate dose of GTX by current standards, and overall success could not be demonstrated. However, 100% of patients who received at least four GTX, and 80% of those receiving at least three GTX survived, as compared with only 30% survival of controls. In the other study with partial benefit," no advantage for GTX could be demonstrated when all patients were analyzed. However, when the subgroup of patients with persistent bone marrow (BM) failure was analyzed separately, 75% of those receiving GTX responded favorably compared with only 20% of controls. This indicated that transfused PMN were likely to benefit patients with persistently severe neutropenia, but not those with recovering marrow function. Thus, some measure of success for GTX was evident in five of the seven controlled studies. However, success was not uniform, as evidenced by two negative studi e~.~. '~ One explanation for the inconsistent success of the controlled studies is evident on critical analysis of the adequacy ofGTX support (Table 3) compatibility."-I3 In contrast, the four with partial or no success can be legitimately criticized in light of current technology. Three of these studies'" were conducted before 1977, and both the quality and quantity of PMNs transfused at that time were clearly inferior to those available today. Patients in the two studies reporting partial success received large numbers of PMNs collected by filtration leukapheresis.**Io The functions of these cells are defective, and PMNs collected by this technique are no longer transfused. Although both of the studies reporting no success used PMNs collected by centrifugation le~kapheresis,'.~~ the dose was extremely low (0.4 to 0.5 X 10" per concentrate). This daily dose is approximately 20% to 25% of the number of PMNs that can be administered currently, and it is not surprising that GTX were unsuccessful. Were the same practice followed in platelet transfusion therapy (ie, giving platelet concentrates containing only 1 X 10" platelets instead of the usual dose of 4 X lo"), would we not incorrectly question the established efficacy of platelet transfusions? Although the number of controlled trials is modest, GTX appear likely to offer benefit to infected neutropenic patients, providing that adequate numbers of compatible PMNs are given. In addition to inadequate PMN dose, at least two other factors might help explain the lack of success in all studies. Investigators in two8,l4 of the four somewhat negative studies8-10,14 made no provisions for the possibility of leukocyte incompatibility and selected donors solely on the basis of erythrocyte compatibility. Finally, control subjects responded reasonably well to antibiotics alone in both of the negative studies>I4 a situation making it difficult to demonstrate a benefit for the addition of GTX.
Accepting the evidence that GTX are likely to offer benefit when PMNs are collected from compatible donors in adequate dosage, the most frequent condition for which GTX are prescribed in neutropenic patients is bacterial sepsis that has failed to respond to appropriate antibiotic therapy. Most neutropenic patients with bacterial sepsis, who experience BM recovery during the early days of infection, will respond to antibiotics
The majority of patients with newly diagnosed, acute leukemia that experience successful induction chemotherapy fit into this category, and these patients almost never require GTX. In contrast, septic patients with persistent, severe neutropenia caused by continuing BM failure may benefit when GTX are added to antibiotic therapy.' Examples are patients with relapsed leukemia undergoing investigational chemotherapy and recipients of BM grafts in whom marrow recovery may be delayed for at least 3 weeks. Regarding the use of GTX to treat systemic infection with yeast and fungi and the other infections listed in Table I , information published to date is insufficient to definitively determine efficacy. However, on the basis of studies in animalsl5,I6 and occasional reports in human~,l~-'~ therapeutic GTX might be considered as treatment for disseminated yeast and fungal infections. In support, the benefit of GTX in treating progressive fungal infections in patients with chronic granulomatous disease has been striking.
To determine whether or not a role for therapeutic GTX exists, individual physicians should survey the outcome of bacterial, yeast, and fungal sepsis in their own neutropenic patients. If infections in these patients respond promptly to antibiotics alone and survival approaches 1009' 0, GTX are unnecessary and should not be used because the benefits would not outweigh the potential risks. However, when significant numbers of infected, neutropenic patients fail to respond to antibiotics alone, the addition of GTX should be considered along with other modifications of therapy (eg, selection of different antibiotics, closer monitoring of antibiotic For personal use only. on October 25, 2017. by guest www.bloodjournal.org From blood levels, 1V gammaglobulin, or recombinant myeloid growth factors).
Regarding the last, both G-CSF and granulocyte-macrophage CSF (GM-CSF) have been used successfully to accelerate BM recovery following chemotherapy and to diminish the development of infections and need for prolonged hospitalization during the period of marrow hypoplasia.22323 In contrast to the success in preventing neutropenic infections, the role of G-CSF and GM-CSF in the treatment of established infections is more controversial, particularly following dose-intensified regimens for the treatment of acute myelogenous leukemia. Thus, the place for recombinant myeloid growth factors in the treatment of neutropenic patients with progressive infections is incompletely defined. Currently, it seems reasonable to initiate therapy with antibiotics and recombinant growth factors and to consider adding GTX to treat patients with severe bacterial, yeast, or fungal infections that continue to progress despite initial measures.
Once the decision to use therapeutic GTX has been made, they must be administered effectively. As a minimum, a daily infusion of 2 to 3 X IOLo PMNs (not < I X 10") should be given to patients with severe, persistent neutropenia (<0.5 X 109/L) who have infections that have failed to respond to a reasonable course (approximately 48 hours) of combination antibiotics. Daily GTX are continued either until the infection has resolved or the blood PMN count has increased to > O S X 109/L. It seems logical that patients with evidence of alloimmunization (platelet refractoriness, antileukocyte antibodies, repeat febrile transfusion reactions, or posttransfusion pulmonary infiltrates) should receive GTX from donors selected to be as leukocyte compatible as possible by HLAmatching and/or leukocyte cross-matching. However, it has not been clearly shown that these attempts to improve compatibility, in fact, increase success of GTX in alloimmunized patients.
FEASIBILITY OF STIMULATING DONORS WITH G-CSF
Bensinger et a1 clearly show that G-CSF can be administered repetitively to normal blood donors for purposes of collecting extraordinary numbers of PMNs for transfusion.' Currently, granulocyte concentrates contain 2 to 3 x 10" PMNs per unit, when collected from steroid-stimulated donors by large volume, centrifugation leukapheresis using hydroxyethyl s t a r~h .~~,~' In contrast, a mean of 4.16 X 10" were collected from donors stimulated with G-CSF.' Donors received G-CSF repetitively for several days and did not experience clinically significant adverse effects. Donor blood PMN counts and PMN yields were maintained for several days, during the period of daily G-CSF administration, to suggest that a limited number of compatible donors (perhaps one) might provide all GTX for a single patient.
Despite these very promising findings, a number of issues must be resolved before the use of G-CSF to stimulate PMN donors becomes standard practice in blood banking. Information from Bensinger et all is limited and must not be overextended. The most serious limitation is the lack of control subjects, studied concurrently, while undergoing leukapheresis performed using optimal techniques. The control group consisted of only 13 donors, who were studied over the rather lengthy interva of 4% years. Leukapheresis of control donors was not performed optimally: steroid stimulation was not used; the dose of hydroxyethyl starch (100 mL) was insufficient; and it seemed unlikely that large volumes (IO L) of donor blood were processed per each collection. Thus, it is not possible to accurately quantitate the superiority of G-CSF stimulation versus standard method^,^^.^' in terms of PMN yields.
Likewise, it is difficult to be completely assured about the lack of toxicity from G-CSF, partly because of the lack of suitable controls and partly because the eight study subjects themselves experienced leukapheresis procedures by somewhat inconsistent techniques.' The volume of donor blood processed varied from 7 to 12 L per procedure. Doses of hydroxyethyl starch were extremely variable, with many being inadequate.25326 Hydroxyethyl starch (pentastarch) was omitted from some collection procedures because of fluid retention, and the yield of PMN would be expected to be extremely small, possibly providing a granulocyte concentrate containing so few PMNs that the value of the GTX could be questioned.26 Although fluid retention can occur following pentastarch infusion, it is quite short-lived because this form of hydroxyethyl starch is eliminated from the bloodstream, almost entirely, within 24 h o~r s .~~,~~ Because of this rapid elimination, extreme fluid retention would not be expected at the usual doses of pentastarch used for leukapheresis, and the possibility of a contributing or additive role for G-CSF should be explored.
Finally, the higher blood PMN count 24 hours posttransfusion, in recipients of GTX from G-CSF-stimulated donors, is confounded by the fact that recipients also were receiving G-CSF.' Although not stated by Bensinger et al,' it seems unlikely that recipients of GTX from control donors received G-CSF. Thus, it is impossible to distinguish the effects of G-CSF on transfused donor PMNs from effects of G-CSF in recipients, particularly if an additive or synergistic effect might occur. In this regard, a control group of patients being treated with G-CSF and receiving GTX, prepared by optimal methods without G-CSF stimulation of donors, should help.
Thus, the report of Bensinger et all is important and, because it offers the opportunity to collect large numbers of PMNs from the same donor repetitively for several days, should rekindle interest in therapeutic GTX. However, the investigators are quite correct to caution that further studies are warranted. Not only must the effects of G-CSF in normal donors be more completely defined, but the properties of PMNs collected by this technique should be investigated, and the efficacy of GTX as treatment for infections must be established by clinical studies of patients receiving modem supportive care.
